Psychedelic-Assisted Therapy and the Default Mode Network

The default mode network (DMN) was identified almost by accident. In the late 1990s and early 2000s, neuroimaging researchers noticed something unexpected: certain brain regions were consistently more active when subjects were resting — doing nothing — than when they were engaged in focused cognitive tasks. The conventional assumption had been that the brain was essentially idle during rest. It wasn't.

Marcus Raichle and his colleagues at Washington University formally described the DMN in 2001, identifying a network of brain regions including the medial prefrontal cortex (mPFC), posterior cingulate cortex (PCC), precuneus, and angular gyrus. These regions show correlated activity during rest, self-referential thinking, mind-wandering, and autobiographical memory retrieval.

The DMN is, in essence, the neural substrate of your sense of self. It is the network that generates the ongoing internal narrative — the voice in your head that reviews the past, plans the future, evaluates social relationships, and constructs the continuous story of who you are. It is also the network most strongly implicated in rumination, self-criticism, and the rigid thought patterns characteristic of depression, anxiety, OCD, and addiction.

In healthy individuals, the DMN activates during rest and deactivates during focused external tasks. This flexibility — the ability to toggle between self-referential processing and task-focused engagement — is a hallmark of healthy cognition.

In depression, the DMN is hyperactive and inflexible. It dominates brain activity even during tasks that should suppress it. The medial prefrontal cortex, in particular, shows excessive connectivity with other DMN nodes, creating a self-reinforcing loop of negative self-referential thought. Rumination — the repetitive, involuntary focus on negative thoughts and feelings — correlates directly with DMN hyperconnectivity.

Similar patterns appear across multiple psychiatric conditions. In addiction, the DMN encodes rigid habitual patterns and self-narratives ("I'm an addict, I can't change"). In PTSD, hyperactive DMN connectivity maintains trauma-related rumination and hypervigilance. In obsessive-compulsive disorder, the DMN's rigidity manifests as intrusive thoughts and compulsive behavioral loops.

The common thread is pathological inflexibility: the brain gets stuck in patterns it cannot break out of through willpower alone. The DMN, which normally provides a useful sense of continuity and self-reference, becomes a prison of recursive negative thinking.

This framing has profound implications for treatment. If mental illness involves a network that is too rigid, then effective treatment might involve making that network more flexible — even temporarily. This is precisely what psychedelics appear to do.

The first modern neuroimaging study of psilocybin, published by Robin Carhart-Harris and colleagues at Imperial College London in 2012, produced a result that surprised many neuroscientists: psilocybin dramatically reduced activity in the DMN. The subjective experience of ego dissolution — the feeling of boundaries between self and world dissolving — correlated directly with the degree of DMN deactivation.

Subsequent studies have refined this picture. Psilocybin doesn't simply suppress the DMN — it desynchronizes it. The normally tightly correlated activity between DMN nodes becomes disordered, while novel connections form between brain networks that don't typically communicate. The technical term is "entropic brain activity" — a state of increased neural complexity and decreased network segregation.

A landmark 2025 study published in Cell demonstrated that psilocybin triggers activity-dependent rewiring of large-scale cortical networks. Using calcium imaging in mice, researchers observed that psilocybin increased trial-by-trial variability in neural responses — the brain became less predictable, less rigid, more exploratory. This wasn't random noise. It was structured reorganization that persisted for weeks after a single dose.

The 5-HT2A receptor is the primary mediator. Psilocybin (technically psilocin, its active metabolite) is a serotonin 2A receptor agonist. 5-HT2A receptors are densely concentrated in cortical layer V pyramidal neurons — the same neurons that form the backbone of the DMN. Activation of these receptors triggers a cascade of intracellular signaling through the mTOR and AMPA receptor pathways that promotes neuritogenesis (new neurite growth), spinogenesis (new dendritic spines), and synaptogenesis (new synaptic connections).

The result is a two-phase process: acute disruption of rigid network patterns during the psychedelic experience, followed by a window of enhanced neuroplasticity lasting days to weeks afterward. This plasticity window is when therapeutic integration occurs — the period during which new, healthier patterns of thought and behavior can be established.

The clinical evidence for psilocybin-assisted therapy has reached a critical mass that can no longer be dismissed as preliminary.

COMPASS Pathways completed two Phase 3 trials of COMP360 (synthetic psilocybin) for treatment-resistant depression — depression that has failed to respond to at least two conventional antidepressant medications. The results were sufficient for COMPASS to plan an FDA approval filing in late 2026. If approved, COMP360 would be the first psychedelic medicine to receive FDA clearance.

Cybin's CYB003 — a deuterated psilocybin analog with improved pharmacokinetics — holds FDA Breakthrough Therapy designation for major depressive disorder, a designation reserved for drugs that show substantial improvement over existing treatments.

Johns Hopkins University's Center for Psychedelic and Consciousness Research has published results showing psilocybin-assisted therapy produced rapid and sustained antidepressant effects, with 67% of participants in remission at 4 weeks and many maintaining improvement at 12 months. Their addiction research showed promising results for tobacco cessation, with 80% abstinence at 6 months compared to <35% for the best conventional treatments.

The mechanism that unifies these diverse applications is DMN modulation. Depression, addiction, and PTSD all involve rigid, self-referential neural patterns maintained by DMN hyperconnectivity. Psilocybin disrupts those patterns and opens a window for reorganization. The therapeutic context — preparation, guided session, integration therapy — provides the framework for constructive reorganization rather than chaos.

The DMN connection to tinnitus is an area of active research that aligns directly with the ExtraLife Hearing research hypothesis. Chronic tinnitus involves maladaptive neural patterns — self-reinforcing loops in the auditory cortex that generate phantom sound. These patterns share key features with the rigid DMN-mediated patterns seen in depression and addiction: they are involuntary, self-reinforcing, and resistant to willpower-based intervention.

Neuroimaging studies have demonstrated altered DMN connectivity in tinnitus patients. The PCC (a core DMN hub) shows abnormal functional connectivity with auditory cortex regions in chronic tinnitus. The medial prefrontal cortex — the same DMN node hyperactive in depression — shows altered patterns that correlate with tinnitus distress ratings.

The ExtraLife hypothesis is that psychedelic-assisted neuroplasticity could disrupt the rigid auditory cortex patterns that maintain tinnitus, just as it disrupts the rigid DMN patterns that maintain depression. If psilocybin can desynchronize pathological neural networks and open a window for rewiring, the auditory cortex networks sustaining tinnitus may be amenable to the same intervention.

This is investigational. No clinical trials have tested psilocybin specifically for tinnitus. But the mechanistic rationale is grounded in the same neuroscience that supports psilocybin's use in depression and addiction. The ExtraLife research initiative aims to bridge that gap — bringing the DMN-disruption framework from psychiatric research into the auditory neuroscience domain.

The regulatory landscape for psychedelic-assisted therapy is evolving more rapidly than most people realize. In August 2025, the DEA forwarded a psilocybin rescheduling petition to HHS for scientific review — a prerequisite for potential reclassification from Schedule I ("no accepted medical use") to Schedule II or lower.

COMPASS Pathways' planned FDA filing for COMP360 in late 2026 could create the first FDA-approved psilocybin medicine. If approved, it would establish a regulatory pathway that other psychedelic medicines — and other indications — could follow.

Dr. Sue Sisley's work at the Scottsdale Research Institute is pushing complementary boundaries: the first FDA-approved trial of whole psilocybin mushrooms (rather than synthetic psilocybin) for PTSD. The whole-mushroom approach tests the "entourage effect" hypothesis — that the full spectrum of mushroom compounds may produce different effects than isolated psilocybin.

State-level initiatives are creating parallel pathways. Oregon's Measure 109 established the first state-regulated psilocybin therapy framework. Colorado followed with similar legislation. Arizona has active legislation (SB1555) for licensing psychedelic therapy centers.

At ExtraLife, we support this research ecosystem because the science is compelling and the unmet need is enormous. Our role is not to administer psychedelic therapy — it is to fund research, educate our community, and be ready to incorporate evidence-based psychedelic protocols when the regulatory framework permits.